[go: up one dir, main page]

DE69917074D1 - Optisch aktives pyridyl-4h-1,2,4-oxadiazinderivat und seine verwendung zur behandlung von gefässkrankheiten - Google Patents

Optisch aktives pyridyl-4h-1,2,4-oxadiazinderivat und seine verwendung zur behandlung von gefässkrankheiten

Info

Publication number
DE69917074D1
DE69917074D1 DE69917074T DE69917074T DE69917074D1 DE 69917074 D1 DE69917074 D1 DE 69917074D1 DE 69917074 T DE69917074 T DE 69917074T DE 69917074 T DE69917074 T DE 69917074T DE 69917074 D1 DE69917074 D1 DE 69917074D1
Authority
DE
Germany
Prior art keywords
oxadiazin
derivative
treatment
optically active
vascular diseases
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69917074T
Other languages
English (en)
Other versions
DE69917074T2 (de
Inventor
Andrea Jednakovits
Laszleta Ueroegdi
Laszlo Denes
Istvan Kurucz
Ede Marvanyos
Mihaly Barabas
Erno Bacsy
Zsuzsanna Korom
Zoltan Nagy
Laszlo Uerge
Jeno Szilbereky
Karoly Acsai
Peter Krajcsi
Zita Csakai
Magdolna Toeroek
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
LadRx Corp
Original Assignee
Biorex Kutato Fejleszto Kft
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Biorex Kutato Fejleszto Kft filed Critical Biorex Kutato Fejleszto Kft
Publication of DE69917074D1 publication Critical patent/DE69917074D1/de
Application granted granted Critical
Publication of DE69917074T2 publication Critical patent/DE69917074T2/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5355—Non-condensed oxazines and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Vascular Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Urology & Nephrology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
DE69917074T 1998-12-14 1999-12-07 Optisch aktives pyridyl-4h-1,2,4-oxadiazinderivat und seine verwendung zur behandlung von gefässkrankheiten Expired - Lifetime DE69917074T2 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
HU9802897 1998-12-14
HU9802897A HU226617B1 (en) 1998-12-14 1998-12-14 Optically active pyridyl-4h-1,2,4-oxadiazine derivatives, and pharmaceutical composition containing the compound as active ingredient
PCT/HU1999/000095 WO2000035914A1 (en) 1998-12-14 1999-12-07 Optically active pyridyl-4h-1,2,4-oxadiazine derivative and its use in the treatment of vascular diseases

Publications (2)

Publication Number Publication Date
DE69917074D1 true DE69917074D1 (de) 2004-06-09
DE69917074T2 DE69917074T2 (de) 2005-05-12

Family

ID=10991166

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69917074T Expired - Lifetime DE69917074T2 (de) 1998-12-14 1999-12-07 Optisch aktives pyridyl-4h-1,2,4-oxadiazinderivat und seine verwendung zur behandlung von gefässkrankheiten

Country Status (27)

Country Link
US (1) US6384029B1 (de)
EP (1) EP1147105B1 (de)
JP (2) JP2002532498A (de)
KR (1) KR100661774B1 (de)
AT (1) ATE266027T1 (de)
AU (1) AU765336B2 (de)
BG (1) BG65179B1 (de)
BR (1) BR9913982A (de)
CA (1) CA2340734C (de)
CZ (1) CZ300764B6 (de)
DE (1) DE69917074T2 (de)
DK (1) DK1147105T3 (de)
EE (1) EE04551B1 (de)
ES (1) ES2219091T3 (de)
HR (1) HRP20010133B1 (de)
HU (1) HU226617B1 (de)
IL (1) IL141515A (de)
NO (1) NO317649B1 (de)
PL (1) PL196584B1 (de)
PT (1) PT1147105E (de)
RS (1) RS50129B (de)
RU (1) RU2222538C2 (de)
SI (1) SI1147105T1 (de)
SK (1) SK285582B6 (de)
UA (1) UA70340C2 (de)
WO (1) WO2000035914A1 (de)
ZA (1) ZA200101182B (de)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA04006716A (es) 2002-01-11 2004-11-10 Biorex Kutato Es Rejleszt Rt Derivados de carboxamidina y su uso en el tratamiento de enfermedades vasculares.
KR100678577B1 (ko) * 2006-09-11 2007-02-06 조만규 가정용 분전함
DK2318032T3 (da) 2008-06-26 2012-06-11 Orphazyme Aps Anvendelse af Hsp70 som regulator af enzymatisk aktivitet
WO2010058779A1 (ja) 2008-11-18 2010-05-27 参天製薬株式会社 ピリジン－３－カルバルデヒド ｏ－（ピペリジン－１－イル－プロピル）－オキシム誘導体を有効成分として含有する網脈絡膜変性疾患の治療剤
US9662375B2 (en) 2010-11-30 2017-05-30 Orphazyme Aps Methods for increasing intracellular activity of Hsp70
HUP1100534A2 (en) 2011-09-26 2013-04-29 Balazs Dr Hazay Pharmaceutical composition for the treatment of muscle atrophy
CN107106494B (zh) 2014-09-15 2021-12-21 奥菲泽米有限公司 阿瑞洛莫制剂
US10898476B2 (en) 2016-04-13 2021-01-26 Orphazyme A/S Heat shock proteins and cholesterol homeostasis
HRP20210047T1 (hr) 2016-04-29 2021-04-16 Orphazyme A/S, c/o COBIS A/S Arimoclomol za liječenje poremećaja povezanih s glukocerebrozidazom
BR112019024667A2 (pt) 2017-05-24 2020-06-16 Orphazyme A/S Uso de um agente bioativo, e, de uma composição
AU2019276048B2 (en) 2018-05-28 2025-09-04 Zevra Denmark A/S Hsp70 protein levels in PBMC samples as biomarker for disease
KR20230128462A (ko) 2020-11-19 2023-09-05 제브라 덴마크 에이/에스 아리모클로몰 시트레이트 및 이의 중간체를 제조하기 위한 공정

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AT395853B (de) * 1991-01-31 1993-03-25 Chem Pharm Forsch Gmbh Neue imidazolderivate, verfahren zu ihrer herstellung und ihre verwendung
HU222994B1 (hu) * 1995-11-02 2004-01-28 BIOREX Kutató és Fejlesztő Rt. Hidroxilaminszármazékok és azok alkalmazása sejtek molekuláris chaperon-termelésének fokozására alkalmas gyógyszerkészítmények előállítására
AU7324196A (en) * 1995-11-03 1997-05-22 Global Trading Uk Limited Apparatus for dispensing and filling bags at a checkout counter of a supermarket
UA64716C2 (en) * 1996-08-09 2004-03-15 Pharmaceuticals for therapy or prevention of illnesses connected with dysfunction of vascular endothelial cells

Also Published As

Publication number Publication date
JP5620340B2 (ja) 2014-11-05
NO20012310L (no) 2001-05-10
PT1147105E (pt) 2004-07-30
EP1147105B1 (de) 2004-05-06
AU1790600A (en) 2000-07-03
US6384029B1 (en) 2002-05-07
UA70340C2 (en) 2004-10-15
CA2340734C (en) 2008-10-21
SK285582B6 (sk) 2007-04-05
DK1147105T3 (da) 2004-06-01
BR9913982A (pt) 2001-06-12
BG105342A (en) 2001-12-29
NO317649B1 (no) 2004-11-29
RU2222538C2 (ru) 2004-01-27
SI1147105T1 (en) 2004-08-31
EP1147105A1 (de) 2001-10-24
EE04551B1 (et) 2005-10-17
AU765336B2 (en) 2003-09-18
HU9802897D0 (en) 1999-02-01
HUP9802897A3 (en) 2001-08-28
JP2011201916A (ja) 2011-10-13
DE69917074T2 (de) 2005-05-12
IL141515A (en) 2005-09-25
NO20012310D0 (no) 2001-05-10
KR20010073129A (ko) 2001-07-31
EE200100188A (et) 2002-08-15
WO2000035914A1 (en) 2000-06-22
CZ20011550A3 (cs) 2001-08-15
HUP9802897A2 (hu) 2000-11-28
JP2002532498A (ja) 2002-10-02
CZ300764B6 (cs) 2009-08-05
BG65179B1 (bg) 2007-05-31
ES2219091T3 (es) 2004-11-16
HRP20010133B1 (en) 2005-02-28
RS50129B (sr) 2009-03-25
HU226617B1 (en) 2009-04-28
SK2342001A3 (en) 2001-08-06
KR100661774B1 (ko) 2006-12-28
ZA200101182B (en) 2002-02-12
CA2340734A1 (en) 2000-06-22
PL196584B1 (pl) 2008-01-31
PL346767A1 (en) 2002-02-25
HRP20010133A2 (en) 2002-02-28
YU25001A (sh) 2004-07-15
ATE266027T1 (de) 2004-05-15
IL141515A0 (en) 2002-03-10

Similar Documents

Publication Publication Date Title
BG106825A (en) Substituted oxazolidinones and their use in the field of blood coagulation
ATE334668T1 (de) Pharmazeutische zusammensetzung zur behandlung von neurologischen und neuropsychiatrischen erkrankungen
RU93058531A (ru) Фторалкоксибензиламинные производные азотсодержащих гетероциклов, фармацевтическая композиция, способ лечения
SE7903186L (sv) Cerebralverksamt medel
ATE238792T1 (de) Verwendung von makroliden zur behandlung von glaukom
DE69917074D1 (de) Optisch aktives pyridyl-4h-1,2,4-oxadiazinderivat und seine verwendung zur behandlung von gefässkrankheiten
UA35567C2 (uk) Фармацевтичний препарат для лікування хворих з порушеннями функції коагуляції, спосіб лікування таких хворих, спосіб одержання фармацевтичного препарату
ATE201992T1 (de) Carbostyrilderivat zur behandlung von ophthalmologischen erkrankungen
DE69824576D1 (de) Verwendung von tetrahydropyridinderivaten zur herstellung von arzneimitteln zur behandlung demyelinisierender erkrankungen
ATE149488T1 (de) Hiv-protease inhibitoren, verwendbar für die behandlung von aids
DE69500673D1 (de) Arzneimittel zur therapeutischen und prophylaktischen Behandlung von Krankheiten, die durch Hyperplasie der glatten Muskelzellen bedingt sind
PT652874E (pt) 2-heterociclico-5-hidroxi-1,3-pirimidinas uteis como agentes anti-inflamatorios
DE60018704D1 (de) Bretyliumhaltige zusammensetzungen und kits und deren verwendung zur vorbeugung und behandlung cardiovaskulärer erkrankungen
DE69307674D1 (de) HIV-Proteaseinhibitoren und ihre Verwendung zur Behandlung von AIDS
HUP0000110A2 (hu) Azaciklusos, azabiciklusos vagy tetrahidropiridinszármazékokat tartalmazó, fájdalom kezelésére alkalmas gyógyászati készítmények
DE69402004D1 (de) Beta-mercapto-propanamidderivate verwendbar zur Behandlung kardiovaskularer Krankheiten oder Erkrankungen
DE69103773D1 (de) Derivate von hydroxaminsäure die lipoxygenase hemmen.
DE69418110D1 (de) N-Heteroaryl substituierte Propanamid-Derivate brauchbar zur Behandlung cardiovascularer Krankheiten
DE69928814D1 (de) Verwendung von tgf-beta inhibitoren zur behandlung von cerebralen krankheiten
DE60121978D1 (de) 7-CHLOR-4-HYDROXY-2-(2-PYRIDYLETHYL)-1,2,5,10-TETRAHYDROPYRIDAZINOi4,5-BöCHINOLIN-1,10-DIONE UND IHRE VERWENDUNG ZUR BEHANDLUNG VON SCHMERZEN
ATE283269T1 (de) 5-(heteroaryl)alkyl)-3-oxo-pyrido(1,2- a)benzimidazol-4-carboxamid (pbi) derivate zur behandlung von störungen des zentralen nervensystems
ATE212842T1 (de) Quinoxalin-derivate zur behandlung von tinnitus
DE68926222D1 (de) Verwendung von 1,2,3,4-Tetrahydroacridinen zur Behandlung von AIDS, sowie Verbindungen
DE69916103D1 (de) 3-alkoxylbenzylaminderivate und ihre verwendung als arzneimittel zur behandlung von schizophrenie

Legal Events

Date Code Title Description
8364 No opposition during term of opposition
8327 Change in the person/name/address of the patent owner

Owner name: CYTRX CORP., LOS ANGELES, CALIF., US